NFE2L1 and Kennedy disease: Collectively, these findings underscore NFE2L1 as a key regulator of proteasome biogenesis and a promising therapeutic target for restoring proteolytic capacity in aggregation disorders.22,39,40 Among current pharmacological approaches, the curcumin derivative ASC-JM17 has emerged as a notable candidate for modulating both the NFE2L1 and NFE2L2 pathways.41,42 This compound has received orphan drug designation by the European Medicines Agency (EMA; EU/3/16/1639) for the treatment of Kennedy's disease.